Abhijit Saste
Hematology & Oncology · Sylvania, OHNPI 1639361850
Payments from drug & device makers
Across 163 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$349
- Seagen Inc.$291
- Novartis$284
- Genentech USA, Inc.$225
- Pfizer$192
- Amgen$186
- plus $2K from 34 others
What the payments were for
- Food & beverage$2,80691%
- Education$2949%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 24 | $349 |
| Seagen Inc. | 9 | $291 |
| Novartis | 16 | $284 |
| Genentech USA, Inc. | 10 | $225 |
| Pfizer | 11 | $192 |
| Amgen | 10 | $186 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $163 |
| Astellas Pharma US Inc | 8 | $151 |
| Johnson & Johnson | 7 | $120 |
| Incyte Corporation | 4 | $91 |
| E.r. Squibb & Sons, L.L.C. | 6 | $82 |
| AstraZeneca(2 entities) | 3 | $71 |
| AbbVie | 3 | $70 |
| Adaptive Biotechnologies Corporation | 3 | $66 |
| Sanofi | 4 | $66 |
| Eisai Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Bayer | 3 | $47 |
| Beigene USA, Inc. | 2 | $45 |
| Rigel Pharmaceuticals, Inc. | 2 | $42 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| Gilead | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Array Biopharma Inc | 2 | $34 |
| Sobi, Inc | 2 | $32 |
| Exelixis Inc. | 2 | $32 |
| Merck | 2 | $28 |
| Genmab U.S., Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| G1 Therapeutics, Inc. | 1 | $14 |
| Fortovia Therapeutics, Inc. | 1 | $13 |
| AVEO Pharmaceuticals, Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $13 |
| Organon | 1 | $11 |
How this compares
$3,100 in reported general payments places this provider in the 40th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 27 | $394,604 |
| RevlimidLenalidomide | 22 | $324,757 |
| ScemblixAsciminib Hydrochloride | 14 | $291,810 |
| Lenalidomide | 24 | $270,627 |
| KisqaliRibociclib Succinate | 13 | $178,788 |
| BosulifBosutinib | 11 | $161,559 |
| VenclextaVenetoclax | 17 | $160,937 |
| CabometyxCabozantinib S-Malate | 11 | $143,067 |
| NubeqaDarolutamide | 12 | $133,343 |
| BrukinsaZanubrutinib | 14 | $110,347 |
| CalquenceAcalabrutinib Maleate | 12 | $90,185 |
| Abiraterone Acetate | 31 | $86,367 |
| EliquisApixaban | 88 | $75,075 |
| Everolimus | 13 | $44,180 |
| GleostineLomustine | 17 | $14,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix, Kisqali | $284 | $470,59827 claims |
| Johnson & JohnsonErleada | $120 | $394,60427 claims |
| Bristol Myers SquibbRevlimid | $349 | $324,75722 claims |
| PfizerBosulif, Eliquis | $192 | $236,63499 claims |
| AbbVieVenclexta | $70 | $160,93717 claims |
| Exelixis Inc.Cabometyx | $32 | $143,06711 claims |
| BayerNubeqa | $47 | $133,34312 claims |
| Beigene USA, Inc.Brukinsa | $45 | $110,34714 claims |
| AstraZenecaCalquence | $71 | $90,18512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Sylvania
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.